Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo Clear all

Conditions: Chronic Pain, Osteoarthritis
Interventions: active low-intensity transcranial electrical stimulation/active transcranial ultrasound, Sham low-intensity transcranial electrical stimulation/sham transcranial ultrasound; Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Short Bowel Syndrome
Interventions: NTRA-9620, Placebo; Drug
Lead sponsor: Elgan Pharma Ltd.; Industry
Eligibility: 2 Weeks to 52 Weeks
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 8
States / cities: Palo Alto, California • Hartford, Connecticut • Gainesville, Florida + 5 more

Conditions: Atopic Dermatitis
Interventions: Etokimab, Placebo; Biological · Drug
Lead sponsor: AnaptysBio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 37
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Encino, California + 34 more

Conditions: Ventricular Tachycardia
Interventions: Dantrolene/Ryanodex, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Keratoconjunctivitis Sicca
Interventions: Pimecrolimus, Vehicle; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Brain Health, Brain Function, Brain Development
Interventions: Fish Oil, Safflower Oil; Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Male only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Heart Failure, Diabetes
Interventions: Thiamine, Placebo; Drug
Lead sponsor: Baystate Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Boston, Massachusetts • Springfield, Massachusetts

Conditions: Dyslipidemias, High Cholesterol, Hypercholesterolemia
Interventions: Obicetrapib; Drug
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 19
States / cities: Anniston, Alabama • Huntington Park, California • Los Angeles, California + 15 more

Conditions: Mild Cognitive Impairment
Interventions: Atomoxetine, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 50 Years to 90 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Knee Osteoarthritis
Interventions: HYMOVIS, Placebo; Device
Lead sponsor: Fidia Farmaceutici s.p.a.; Industry
Eligibility: 40 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 21
States / cities: Birmingham, Alabama • Brimingham, Alabama • Phoenix, Arizona + 17 more

Conditions: Colorectal Adenoma
Interventions: Ginger extract, Placebo; Dietary Supplement · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 50 Years to 75 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Albert Lea, Minnesota • Austin, Minnesota • Deer River, Minnesota + 10 more

Conditions: Major Depressive Disorder, Psychotic Disorders
Interventions: ORG 34517; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: HM10760A or placebo; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: US, California

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 26
States / cities: Bell Gardens, California • Long Beach, California • Los Angeles, California + 21 more

Conditions: Asthma
Interventions: Escitalopram, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Memory
Interventions: Donepezil, Placebos; Drug
Lead sponsor: Stanford University; Other
Eligibility: 55 Years to 90 Years
Enrollment: 198 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Diabetic Peripheral Neuropathy
Interventions: Erchonia® FX-635™, Placebo Laser; Device
Lead sponsor: Erchonia Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Mesa, Arizona

Conditions: Influenza, Human
Interventions: TCN-032, Placebo; Biological
Lead sponsor: Theraclone Sciences, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COVID-19, COVID
Interventions: Pegylated interferon lambda; Drug
Lead sponsor: Raymond Chung; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Precancerous Condition
Interventions: omega-3 fatty acid, placebo; Dietary Supplement · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 21 Years to 120 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Tinea Pedis, Athlete's Foot
Interventions: Econazole Nitrate Foam 1%, Vehicle Foam; Drug · Other
Lead sponsor: AmDerma; Industry
Eligibility: 12 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: Miramar, Florida • Clinton Township, Michigan • Las Vegas, Nevada + 4 more

Conditions: Healthy
Interventions: PF-06946860, Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Interventions: Solriamfetol 150 MG, Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 40
States / cities: Tucson, Arizona • Bellflower, California • Chino, California + 33 more

Conditions: HIV Infections
Interventions: p24CE1/2 pDNA Vaccine, p55^gag pDNA Vaccine, IL-12 pDNA Adjuvant, Placebo, Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device; Biological · Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: San Francisco, California • Decatur, Georgia • Cleveland, Ohio

Search by objective public record fields.

Effects of tDCS and tUS on Pain Perception in OA of the Knee

Safety and Efficacy Study in Infant With SBS

Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.

Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca

Effect of Fish Oil on Athlete's Executive Function

Thiamine and Acute Decompensated Heart Failure: Pilot Study

Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

Effects of Atomoxetine in Mild Cognitive Impairment

Safety and Effectiveness Study of a Non-Crosslinked HA Alkylamide HYADD(TM) 4 Hydrogel for Osteoarthritis of the Knee

Ginger and Gut Microbiome (GINGER)

Safety Study of ORG 34517 for Major Depression With Psychotic Features

A Study of HM10760A (Long-acting Erythropoietin) in Healthy Adult Caucasian and Japanese Subjects

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Escitalopram in Asthma Patients With Frequent Exacerbation

Memory and Mental Health in Aging

Study of Low Level Laser Therapy to Treat Diabetic Peripheral Neuropathy Foot Pain

Safety Study of Anti-Influenza Virus Monoclonal Antibody to Treat Influenza

Pegylated Interferon Lambda Treatment for COVID-19

Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia

Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis

Singe Dose Study of PF- 06946860 in Healthy Adult Japanese Participants

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA